Abstract: The present invention relates to an immunogenic fusion protein comprising a first amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, which is fused to a second amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a second group B Streptococcus surface protein. Each of the first and the second group B Streptococcus surface protein is selected from the group consisting of Rib protein, Alp1 protein, Alp2 protein, Alp3 protein, Alp4 protein and AlpC protein. The immunogenic fusion protein further comprises at least one amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of the group B Streptococcus surface protein Alp1, Alp2, Alp3 or Alp4.

Abstract: The present invention relates to an immunogenic fusion protein comprising or consisting of an amino acid sequence consisting of: i. a first amino acid sequence part consisting of 170 to 178 amino acids, preferably 174 to 175 amino acids, and having at least 90% sequence identity with the amino acid sequence shown in SEQ ID NO: 7; ii. a second amino acid sequence part consisting of 165 to 174 amino acids, preferably 169 to 170 amino acids, and having at least 90% sequence identity with the amino acid sequence shown in SEQ ID NO: 14; and optionally: iii. a linker amino acid sequence part consisting of 1 to 20 amino acids and separating the first amino acid sequence part from the second amino acid part. The immunogenic fusion protein preferably consists of 335 to 372 amino acids, preferably 343 to 353 amino acids, more preferably 343 to 347 amino acids.

Abstract: The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.

Abstract: The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.

Abstract: The present invention relates to an immunogenic fusion protein comprising a first amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, which is fused to a second amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a second group B Streptococcus surface protein. Each of the first and the second group B Streptococcus surface protein is selected from the group consisting of Rib protein, Alp1 protein, Alp2 protein, Alp3 protein, Alp4 protein and AlpC protein. The immunogenic fusion protein further comprises at least one amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of the group B Streptococcus surface protein Alp1, Alp2, Alp3 or Alp4.

Abstract: The present invention relates to an immunogenic fusion protein comprising a first amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, which is fused to a second amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a second group B Streptococcus surface protein. Each of the first and the second group B Streptococcus surface protein is selected from the group consisting of Rib protein, Alp1 protein, Alp2 protein, Alp3 protein, Alp4 protein and AlpC protein. The immunogenic fusion protein further comprises at least one amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of the group B streptococcus surface protein Alp1, Alp2, Alp3 or Alp4.

Abstract: The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.

Abstract: The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.

Abstract: Disclosed herein is an external mixing pressurized two-fluid nozzle for atomising a liquid by means of liquid pressure and gas, comprising an inner feed liquid pipe (1) extending axially between an upstream end and a downstream end, having a feed liquid conduit (2), a feed liquid inlet (3) positioned at the upstream end and a feed orifice (4) positioned at the downstream end, and a co-axial first gas pipe (5) extending radially outside the inner feed liquid pipe (1) and forming a first gas conduit (6) between the first gas pipe (5) and the inner feed liquid pipe (1), the first gas pipe (5) having a gas outlet slit (7) positioned at the downstream end. Said external mixing two-fluid nozzle provides a swirling motion of the gas, which combined with a pressurized feed liquid enables the production of spray dried powder at industrially applicable capacities with low energy consumption and a small particle size.

Abstract: The present invention relates to an immunogenic complex comprising an amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a group B Streptococcus surface protein, and a capsular polysaccharide. The immunogenic complex is capable of eliciting protective immunity against group B Streptococcus. The invention further pertains to an immunogenic product comprising the immunogenic complex and an immunogenic fusion protein, the vaccine, the immunogenic complex, or the immunogenic product for use in a method of preventing or treating a group B Streptococcus infection, as well as a method of preventing or treating a group B Streptococcus infection.

Abstract: Disclosed herein is an external mixing pressurized two-fluid nozzle for atomising a liquid by means of liquid pressure and gas, comprising an inner feed liquid pipe (1) extending axially between an upstream end and a downstream end, having a feed liquid conduit (2), a feed liquid inlet (3) positioned at the upstream end and a feed orifice (4) positioned at the downstream end, and a co-axial first gas pipe (5) extending radially outside the inner feed liquid pipe (1) and forming a first gas conduit (6) between the first gas pipe (5) and the inner feed liquid pipe (1), the first gas pipe (5) having a gas outlet slit (7) positioned at the downstream end. Said external mixing two-fluid nozzle provides a swirling motion of the gas, which combined with a pressurized feed liquid enables the production of spray dried powder at industrially applicable capacities with low energy consumption and a small particle size.

Abstract: The present invention relates to an immunogenic fusion protein comprising a first amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a first group B Streptococcus surface protein, which is fused to a second amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of a second group B Streptococcus surface protein. Each of the first and the second group B Streptococcus surface protein is selected from the group consisting of Rib protein, Alp1 protein, Alp2 protein, Alp3 protein, Alp4 protein and AlpC protein. The immunogenic fusion protein further comprises at least one amino acid sequence having at least 80% sequence identity with the amino acid sequence of the N-terminal region of the group B streptococcus surface protein Alp1, Alp2, Alp3 or Alp4.

Abstract: Disclosed herein is an external mixing pressurized two-fluid nozzle for atomising a liquid by means of liquid pressure and gas, comprising an inner feed liquid pipe (1) extending axially between an upstream end and a downstream end, having a feed liquid conduit (2), a feed liquid inlet (3) positioned at the upstream end and a feed orifice (4) positioned at the downstream end, and a co-axial first gas pipe (5) extending radially outside the inner feed liquid pipe (1) and forming a first gas conduit (6) between the first gas pipe (5) and the inner feed liquid pipe (1), the first gas pipe (5) having a gas outlet slit (7) positioned at the downstream end. Said external mixing two-fluid nozzle provides a swirling motion of the gas, which combined with a pressurized feed liquid enables the production of spray dried powder at industrially applicable capacities with low energy consumption and a small particle size.

Abstract: Disclosed herein is an external mixing pressurized two-fluid nozzle for atomising a liquid by means of liquid pressure and gas, comprising an inner feed liquid pipe (1) extending axially between an upstream end and a downstream end, having a feed liquid conduit (2), a feed liquid inlet (3) positioned at the upstream end and a feed orifice (4) positioned at the downstream end, and a co-axial first gas pipe (5) extending radially outside the inner feed liquid pipe (1) and forming a first gas conduit (6) between the first gas pipe (5) and the inner feed liquid pipe (1), the first gas pipe (5) having a gas outlet slit (7) positioned at the downstream end. Said external mixing two-fluid nozzle provides a swirling motion of the gas, which combined with a pressurized feed liquid enables the production of spray dried powder at industrially applicable capacities with low energy consumption and a small particle size.

Abstract: In a first example of “Body-Area Networking” (“BAN”), a user wishing to access his electronic device ingests a small pill carrying a transmitter. The transmitter's signal carries an identification code that traverses the user's BAN and is read by the device. If the device recognizes that identification code as authenticate, then the device grants the user the desired access. In another example, the user again swallows a transmitter. When the user shakes hands with another person, the signal originating at the ingested transmitter is carried across the BAN of the first user, travels across the handshake to the BAN of the second user, then traverses the second user's BAN to her device. In a third example, a media player transmits audio information across the BAN to a headset worn by the user. The headset receives the signal, demodulates it, and renders the audio to the user.

Abstract: In a first example of “Body-Area Networking” (“BAN”), a user wishing to access his electronic device ingests a small pill carrying a transmitter. The transmitter's signal carries an identification code that traverses the user's BAN and is read by the device. If the device recognizes that identification code as authenticate, then the device grants the user the desired access. In another example, the user again swallows a transmitter. When the user shakes hands with another person, the signal originating at the ingested transmitter is carried across the BAN of the first user, travels across the handshake to the BAN of the second user, then traverses the second user's BAN to her device. In a third example, a media player transmits audio information across the BAN to a headset worn by the user. The headset receives the signal, demodulates it, and renders the audio to the user.

Abstract: In a first example of “Body-Area Networking” (“BAN”), a user wishing to access his electronic device ingests a small pill carrying a transmitter. The transmitter's signal carries an identification code that traverses the user's BAN and is read by the device. If the device recognizes that identification code as authenticate, then the device grants the user the desired access. In another example, the user again swallows a transmitter. When the user shakes hands with another person, the signal originating at the ingested transmitter is carried across the BAN of the first user, travels across the handshake to the BAN of the second user, then traverses the second user's BAN to her device. In a third example, a media player transmits audio information across the BAN to a headset worn by the user. The headset receives the signal, demodulates it, and renders the audio to the user.

Abstract: In a first example of “Body-Area Networking” (“BAN”), a user wishing to access his electronic device ingests a small pill carrying a transmitter. The transmitter's signal carries an identification code that traverses the user's BAN and is read by the device. If the device recognizes that identification code as authenticate, then the device grants the user the desired access. In another example, the user again swallows a transmitter. When the user shakes hands with another person, the signal originating at the ingested transmitter is carried across the BAN of the first user, travels across the handshake to the BAN of the second user, then traverses the second user's BAN to her device. In a third example, a media player transmits audio information across the BAN to a headset worn by the user. The headset receives the signal, demodulates it, and renders the audio to the user.

Abstract: Disclosed herein is an external mixing pressurized two-fluid nozzle for atomising a liquid by means of liquid pressure and gas, comprising an inner feed liquid pipe (1) extending axially between an upstream end and a downstream end, having a feed liquid conduit (2), a feed liquid inlet (3) positioned at the upstream end and a feed orifice (4) positioned at the downstream end, and a co-axial first gas pipe (5) extending radially outside the inner feed liquid pipe (1) and forming a first gas conduit (6) between the first gas pipe (5) and the inner feed liquid pipe (1), the first gas pipe (5) having a gas outlet slit (7) positioned at the downstream end. Said external mixing two-fluid nozzle provides a swirling motion of the gas, which combined with a pressurized feed liquid enables the production of spray dried powder at industrially applicable capacities with low energy consumption and a small particle size.

Abstract: The present invention relates to microcrystallized polyol comprising at least two polyols, wherein said polyols are selected from the group consisting of maltitol, xylitol and lactitol and wherein said composition contains at least 35% by weight of each of at least two of said polyols microcrystallized together into a solid microcrystalline product. The present invention also relates to a process for the microcrystallization of polyols into a polyol composition. The microcrystallized polyol composition can be used in confectionery, foodstuffs, oral hygiene products and pharmaceuticals and in dietetic products.